Chance Pharmaceuticals closes RMB80m Series B round

Chance Pharmaceuticals, a Chinese inhalation drug delivery system platform company, announced that it has completed 80 million yuan in a Series B financing round.

Chance Pharmaceuticals, a Chinese inhalation drug delivery system platform company, announced that it has completed 80 million yuan in a Series B financing round.

This round of financing was invested by companies such as Yipinhong Pharmacy, and the proceeds from this round will be used to promote the clinical research of the company’s research projects, enrich the R&D team and expand the R&D pipeline.

Chance Pharmaceuticals had completed the RMB55m Series A round led by Shenzhen Guozhong Venture Capital in January 2018 with participation from Kaitai Capital and Delian Capital; and received an angel round investment of 10 million yuan from Delian Capital in April 2016.

Chance Pharmaceutical was founded in 2015 and is headquartered in Hangzhou.

It is a high-tech platform company with inhalation preparation and inhaler design and development technology, focusing on the use of its mature micronization technology and advanced particle engineering preparation technology platform and corresponding inhalation device design and evaluation technology platform, to develop powder aerosol products for the treatment of respiratory diseases and non-respiratory diseases, and commercialize the products.

At present, its existing products have entered the clinical research stage.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/06/17/chance-pharmaceuticals-closes-rmb80m-series-b-round/.

Leave a Reply

Your email address will not be published. Required fields are marked *